• Based in San Diego, Human Longevity is fixed on using genome data and analytics to develop new ways to fight age-related diseases.
  • Perkins says the opportunity for humanity -- and Human Longevity -- is the result of the convergence of four trends: the reduction in the cost of genome sequencing (from $100m per genome in 2000, to just over $1,000 in 2014), the vast improvement in computational power, the development of large-scale machine learning techniques and the wider movement of health care systems towards ‘value-based’ models.
  • The "highly secret" Human Longevity business plan is actually very simple, Perkins jokes: the company wants to take large amounts of genome data, subject it to machine learning and analytics, and "radically, disruptively" produce new models for medical care. 

Share This Article